Healthday News - The second major cancer risk is higher in breast cancer survivors than in women in the general population. However, the risk remains low and is driven primarily by opposing breast cancer, BMJ.

Dr. Paul McGalle and colleagues from the University of Oxford in the UK conducted an observational cohort study to assess the long-term risk of second non-brain breast cancer and contralateral breast cancer among women with early invasive breast cancer who received primary breast cancer. The analysis included data from the National Cancer Registration and Analysis Services in England for 476,373 women with breast cancer as the first invasive (index) cancer (1993-2016).

Researchers found that by 2020, 13.6% of women developed non-brain cancer - 2.1% more than expected in the general population - 5.6% developed contralateral side breast cancerThis was 3.1% higher than expected. In younger women, the absolute risk of contralateral breast cancer was greater than in older women. The absolute excess risk of non-breast cancer for up to 20 years was uterine cancer and lung cancer. The standardized incidence rate exceeded a coefficient of at least 1.5 for cancers of the uterus, soft tissue, bone, joints, and salivary glands, but as with acute leukemia, the risk of absolute excess over the 20-year was less than 1% per individual non-breast cancer type. Radiotherapy includes endocrine therapy with increased concurrent breast and lung cancer, increased uterine cancer, and Chemotherapy With the increase in acute leukemia. Approximately 2% of all 64,747 second cancers and 7% of the 15,813 excess second cancers in the cohort can be attributed to adjuvant therapy.

"Many breast cancer survivors believe the risk of a second cancer is much higher than what we estimated," the authors write. "The information from our research can reassure them and help them plan their future."

Summary/Full text